Evidence map›Paper›PMID 40894946›Full record

ArticleJournal of surgical case reports2025

Histological mitotic count is a prognostic marker in vulvar sarcoma: a retrospective case series of 27 patients.

Zejian Lin, Haifeng Gu, Guochen Liu, Lili Liu, Zhimin Liu, Junyun Li, Xinke Zhang, Hua Tu

Abstract readCase Reports
In one paragraph

Article in Journal of surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zejian LinDepartment of Gynecologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Yuexiu District, Guangzhou 510060, Guangdong, China.
Haifeng GuDepartment of Gynecologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Yuexiu District, Guangzhou 510060, Guangdong, China.
Guochen LiuDepartment of Gynecologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Yuexiu District, Guangzhou 510060, Guangdong, China.
Lili LiuDepartment of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Yuexiu District, Guangzhou 510060, Guangdong, China.
Zhimin LiuDepartment of Gynecologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Yuexiu District, Guangzhou 510060, Guangdong, China.
Junyun LiDepartment of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Yuexiu District, Guangzhou 510060, Guangdong, China.
Xinke ZhangDepartment of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Yuexiu District, Guangzhou 510060, Guangdong, China.
Hua TuDepartment of Gynecologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Yuexiu District, Guangzhou 510060, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This retrospective study analyzed 27 vulvar sarcoma patients treated at one institution (2005-2024). Mitotic count significantly predicted outcomes: patients with ≥20 mitoses/high power field (HPF) (N = 8) showed drastically worse recurrence-free survival (recurrence-free survival; hazard ratio [HR] = 15.48, 95% confidence interval [CI] = 2.67-89.70,

Indexed as

mitotic countprognosisvulvar sarcoma

Identifiers

PMID40894946
PMCPMC12398262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.